Ph.D., CSO and Co-Founder, Alithea Bio UG
Biography
Tim Fugmann holds a PhD from ETH Zurich and has directed the target discovery efforts at the Philogen group (CH) before becoming Prof. for mass spectrometry-based proteomics in Germany. He co-founded Alithea Bio to facilitate and accelerate development of peptide HLA-targeted therapeutics such as TCR mimics and TCR T cell therapies. With Alithea his vision is to create a holistic view on the HLA-presented peptides to understand and guide immune reactions in individuals. For this, Alithea has created a large HLA peptide database from 3000 samples covering 1.1 Million ligands and their abundance in health and disease. Further, Alithea can readily identify novel targets and potential on and off-target toxicities. Alithea finally has a collection of HLA-typed healthy tissue samples in which epitopes of interest can be quantified down to few molecules per cell.
Talk
Clinical & Research Tools Showcase:
Alithea Bio UG
Alithea Bio focuses on HLA-presented peptides and facilitates highly sensitive detection and quantification for target discovery, validation and tox prediction. Alithea has a cloud-based HLA peptide database with >1.1 Million epitopes and their abundance in health and disease facilitating precision medicine applications
A holistic view on the HLA peptidome
Big data and highly sensitive MS technology facilitates detection and quantification of clinical HLA peptide targets
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S2 - January 25 2.45 P.M.-4.00 P.M.,Showcase Track S2 - January 26 1.30 P.M.-4.00 P.M.,Showcase Track S2 - January 27 1.15 P.M.-1.30 P.M.
The PMWC 2023 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
